SourceOne takes Sytrinol beyond US

The distributor will work with supplier Solgar to bring Sytrinol for heart health to the European market following what the company says was a successful launch in the US. "Working with Solgar on the launch of Sytrinol in the U.S. was a rewarding and successful experience and we look forward to building on this foundation of success with Solgar in the European market,"​ said Jesse Lopez, president and CEO of SourceOne. The finished product contains Sytrinol, a patented ingredient derived from citrus. The Canadian-developed ingredient is composed of polymethoxylated flavones and tocotrienols. According to SourceOne, clinical studies have shown Sytrinol to reduce total cholesterol by 30 percent, to reduce LDL cholesterol by 27 percent, as well as to lower triglycerides by 34 percent. The antioxidant ingredients is also said to have anti-inflammatory applications. Unlike other cholesterol supplements, Sytrinol is not diet specific and has no known side effects. SourceOne has licensed the worldwide rights to patents and associated intellectual property for the use of Sytrinol in dietary supplements including capsules, bars, beverages and drink mixes. The market for dietary supplements that lower cholesterol is said to be growing as those who suffer from related conditions prefer to take a natural alternative to pharmaceutical products. As such there is room in the market for products such as Syntrinol, if consumers deem them to be effective.